Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Skin Cancer: Page 2
Tempus, Kartos Therapeutics collaborate on CDx for Merkel cell carcinoma treatment
By
LabPulse.com staff writers
The collaboration is aimed at developing a companion diagnostic (CDx) test to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may be responsive to treatment with navtemadlin.
October 7, 2022
Castle Biosciences posts revenue surge, lower net loss in Q2
By
LabPulse.com staff writers
For the period (end-June 30), Castle had revenue of $34.8 million, up from $22.8 million in the second quarter of 2021. The firm delivered 11,034 total test reports in the second quarter, up 57% compared with the same period last year. Castle also pointed to a 44% increase in skin cancer gene expression report test volume.
August 8, 2022
Labcorp launches skin cancer assay
By
LabPulse.com staff writers
Studies have shown that LAG-3 is an immune-oncology target with demonstrable clinical benefit in patients with melanoma. Labcorp said its LAG-3 IHC method has demonstrated performance suitable for analysis of LAG-3 immune cell expression in clinical melanoma samples in a study published May 9 in the Journal of Clinical Pathology.
May 18, 2022
SkylineDx, Mayo Clinic evaluate genetic skin cancer test
By
LabPulse.com staff writers
The test can accurately predict the risk of regional metastasis at the time of melanoma diagnosis, according to SkylineDx.
September 25, 2019
Castle Biosciences moves ahead with skin cancer test
By
LabPulse.com staff writers
In a study of data drawn from patients at 18 centers, researchers identified a preliminary set of genes and developed a predictive algorithm associated with significantly higher risk for the recurrence of cSCC, a nonmelanoma type of skin cancer. The positive predictive value of the prognostic test was 60%, a result the company said compares well with current staging methods.
May 7, 2019
Previous Page
Page 2 of 2